Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
Crossref DOI link: https://doi.org/10.1007/s00535-017-1364-8
Published Online: 2017-07-01
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Seko, Yuya
Sumida, Yoshio
Sasaki, Kazuyo
Itoh, Yoshito
Iijima, Hiroaki
Hashimoto, Toshio
Ishii, Shinichi
Inagaki, Nobuya
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation
License valid from 2017-07-01